THE AOP ORPHAN STORY

Targeting Rare Diseases

AOP Orphan is a European pioneer in the development, production and marketing of treatments for people with rare diseases also known as orphan diseases.

Content:
Bettina Blosse Managing Director Nordic Countries

“Introducing treatments to the Nordic market is a complex task we are eager to master for the benefit of patients!”

Facts & Figures

AOP Orphan is fully dedicated to pharmaceutical and clinical development as well as commercialization of drugs for more than 20 years already.

Our motivation at AOP Orphan is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the Swedish health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases. 

Sweden occupies a special position among many countries where AOP Orphan is represented. In this market, the company began its development in 2017 and this is where AOP Orphan started its activities in the Nordics region. AOP Orphan Sweden is comprised of experienced and qualified team members in the Marketing & Sales, and Medical for all three therapeutic divisions.

 

540,000 
people
PATIENTS WITH RARE DISEASES IN sweden
In Sweden, the definition of a rare disease is defined as rare when it affects 1 in 10 000 individuals. In Sweden 540,000 people have been diagnosed with a rare disease.
AVAILABLE TREATMENTS
In Sweden AOP Orphan provides 8 products. 
8
products
3
areas
THREE THERAPEUTIC AREAS
AOP Orphan Sweden covers three areas of treatments: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders.

Vision & Mission

Milestones